[{"abstract": "AstraZeneca waded into the competitive rheumatoid arthritis market on Tuesday by buying rights to Rigel Pharmaceuticals\u2019 next-generation drug R788 for up to $1.245 billion, Reuters reported.", "web_url": "https://dealbook.nytimes.com/2010/02/17/astra-pays-up-to-1-2-billion-for-arthritis-drug/", "snippet": "AstraZeneca waded into the competitive rheumatoid arthritis market on Tuesday by buying rights to Rigel Pharmaceuticals\u2019 next-generation drug R788 for up to $1.245 billion, Reuters reported.", "lead_paragraph": "AstraZeneca waded into the competitive rheumatoid arthritis market on Tuesday by buying rights to Rigel Pharmaceuticals\u2018 next-generation drug R788 for up to $1.245 billion, Reuters reported.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Astra Pays Up to $1.2 Billion for Arthritis Drug", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "AstraZeneca PLC", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 2, "major": "N"}], "pub_date": "2010-02-17T08:59:28+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "", "_id": "nyt://article/a54bc8f1-211c-5747-9ba9-701d9e981852", "word_count": 451, "uri": "nyt://article/a54bc8f1-211c-5747-9ba9-701d9e981852"}, {"abstract": "Merck posted quarterly revenue above analysts\u2019 estimates on Tuesday, helped by strong sales of its diabetes and allergy drugs, Reuters reported.", "web_url": "https://dealbook.nytimes.com/2010/02/17/in-wake-of-merger-merck-beats-forecasts/", "snippet": "Merck posted quarterly revenue above analysts\u2019 estimates on Tuesday, helped by strong sales of its diabetes and allergy drugs, Reuters reported.", "lead_paragraph": "Merck posted quarterly revenue above analysts\u2019 estimates on Tuesday, helped by strong sales of its diabetes and allergy drugs, Reuters reported.", "source": "The New York Times", "multimedia": [], "headline": {"main": "In Wake of Merger, Merck Beats Forecasts", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "AstraZeneca PLC", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Bristol-Myers Squibb Co", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Wyeth", "rank": 4, "major": "N"}], "pub_date": "2010-02-17T09:56:18+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "", "_id": "nyt://article/2905d6ef-1339-5073-9fd9-192a48d86d7d", "word_count": 293, "uri": "nyt://article/2905d6ef-1339-5073-9fd9-192a48d86d7d"}]